Premium
Graphene Oxide‐Cyclic R10 Peptide Nuclear Translocation Nanoplatforms for the Surmounting of Multiple‐Drug Resistance
Author(s) -
Tu Zhaoxu,
Donskyi Ievgen S.,
Qiao Haishi,
Zhu Zhonglin,
Unger Wolfgang E. S.,
Hackenberger Christian P. R.,
Chen Wei,
Adeli Mohsen,
Haag Rainer
Publication year - 2020
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202000933
Subject(s) - photothermal therapy , multiple drug resistance , materials science , doxorubicin , nanotechnology , conjugated system , in vitro , graphene , in vivo , peptide , chromosomal translocation , drug delivery , drug resistance , biophysics , biology , chemotherapy , biochemistry , microbiology and biotechnology , polymer , gene , genetics , composite material
Multidrug resistance resulting from a variety of defensive pathways in cancer has become a global concern with a considerable impact on the mortality associated with the failure of traditional chemotherapy. Therefore, further research and new therapies are required to overcome this challenge. In this work, a cyclic R10 peptide (cR 10 ) is conjugated to polyglycerol‐covered nanographene oxide to engineer a nanoplatform for the surmounting of multidrug resistance. The nuclear translocation of the nanoplatform, facilitated by cR 10 peptide, and subsequently, a laser‐triggered release of the loaded doxorubicin result in efficient anticancer activity confirmed by both in vitro and in vivo experiments. The synthesized nanoplatform with a combination of different features, including active nucleus‐targeting, high‐loading capacity, controlled release of cargo, and photothermal property, provides a new strategy for circumventing multidrug resistant cancers.